Achieve Life Sciences, Inc. (ACHV)
NASDAQ: ACHV · Real-Time Price · USD
4.485
+0.025 (0.56%)
At close: Dec 26, 2025, 4:00 PM EST
4.494
+0.008 (0.19%)
After-hours: Dec 26, 2025, 7:17 PM EST
Achieve Life Sciences Stock Forecast
Stock Price Forecast
The 2 analysts that cover Achieve Life Sciences stock have a consensus rating of "Strong Buy" and an average price target of $15.5, which forecasts a 245.60% increase in the stock price over the next year. The lowest target is $12 and the highest is $19.
Price Target: $15.5 (+245.60%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Nov 25, 2025.
Analyst Ratings
The average analyst rating for Achieve Life Sciences stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 2 | 2 | 2 | 1 | 1 |
| Buy | 1 | 0 | 0 | 0 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 2 | 2 | 2 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citizens | Citizens | Buy Initiates $19 | Buy | Initiates | $19 | +323.63% | Nov 25, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $12 | Strong Buy | Initiates | $12 | +167.56% | Aug 21, 2025 |
| Rodman & Renshaw | Rodman & Renshaw | Strong Buy Initiates $12 | Strong Buy | Initiates | $12 | +167.56% | Nov 14, 2024 |
| Raymond James | Raymond James | Strong Buy Initiates $20 | Strong Buy | Initiates | $20 | +345.93% | Sep 27, 2024 |
| Oppenheimer | Oppenheimer | Buy Reiterates $11 | Buy | Reiterates | $11 | +145.26% | Aug 15, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
17.12M
EPS This Year
-1.28
from -1.24
EPS Next Year
-1.14
from -1.28
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | n/a | 29.8M | ||||
| Avg | n/a | 17.1M | ||||
| Low | n/a | 5.5M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -1.25 | -0.88 | ||||
| Avg | -1.28 | -1.14 | ||||
| Low | -1.27 | -1.30 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.